Extended Data Table 5 Quality of life: EORTC QLQ-C30 TTD from baseline

From: Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial

  1. Median TTD was derived as a Kaplan-Meier estimate. 95% CI associated with median was computed using the Brookmeyer-Crowley method. HR (95% CI) and P-value were estimated using a stratified Cox proportional hazards regression analysis and stratified log-rank test, respectively, with treatment arm (SG vs. chemotherapy) as covariate and the prior chemotherapy regimens for treatment of metastatic disease (two vs. three/four lines), visceral metastasis (yes/no), and prior treatment with CDK4/6 inhibitors in the metastatic setting (yes/no) as stratification factors. A two-tailed P-value < 0.05 was deemed statistically significant. No adjustments were made for multiple comparisons.
  2. aPatients with baseline scores so poor that it was impossible for the change score to exceed or equal the threshold measure for worsening were excluded.
  3. EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL, quality of life; SG, sacituzumab govitecan; TTD, time to deterioration.
Back to article page